Newsletter
A short monthly email on women's hormonal health — what's new in menopause/HRT, GLP-1 for women, PCOS, and the providers we cover. No spam, no health questionnaires, no behavioral tracking.
What you'll get (preview)
What you'll get
- New brand reviews and quarterly re-verifications
- Treatment news (FDA approvals, brand pivots, compounding changes)
- STRAW+10 stage explainers and symptom deep-dives
- Editorial picks for "best of" categories
What you won't get
- Health questionnaires or symptom intake forms
- Brand-paid sponsored content disguised as editorial
- Affiliate-driven recommendations (we never reorder based on commission)
- More than one email per month — usually less
Reviewed by clinicians
Every newsletter is read by one of our medical advisors before sending. The same standard we apply to site content.
Privacy
We store your email with our newsletter provider (Beehiiv). We don't pass it to brands, never sell it, and don't use it for cross-site tracking. See our privacy policy.
Past issues archive
3 issues and counting. Full text preserved indefinitely.
Compounded GLP-1 pricing drops 18% Q1 2026
Issue #47 · 2026-05-14
Our pricing index shows median compounded semaglutide moved $249→$204/mo. 503A capacity expansion cited. Three new pharmacy partnerships launched.
Topic: glp1 · 3800% open rate
NAMS 2026 update: HRT eligibility window expanded
Issue #46 · 2026-05-07
North American Menopause Society released new position statement. Eligibility extended to age 65 in healthy women. Transdermal estrogen formally preferred over oral.
Topic: menopause · 4200% open rate
PCOS insulin screening criteria narrowed
Issue #45 · 2026-04-30
AACE/ACE 2026 update narrows insulin resistance screening to Rotterdam phenotype A only. Reduces over-screening of phenotypes B/C/D.
Topic: pcos · 3100% open rate